Independent report · Private Markets

Anupam Rasayan and Bliss GVS Pharma: about ₹1,750 Cr all-in

· By Reena

Anand Desai, Managing Director of Anupam Rasayan India · Image: DSIJ

Anand Desai, Managing Director of Anupam Rasayan India · Image: DSIJ

Independent report content

BUYERAnupam Rasayan India Ltd (Surat; NSE: ANURAS), custom synthesis and specialty chemicals, acting with its subsidiary Mates Visa Consultancy Pvt Ltd
TARGETBliss GVS Pharma Ltd (BSE: 506197), Mumbai-listed formulations maker founded 1984, about 91% exports (secondary aggregator)
AGREEMENTShare purchase agreement signed 23 May 2026 · promoter block of 5,09,84,595 shares (47.95%) completed 28 Sep 2026 at ₹299
COMBINED HOLDINGAbout 50.07% with the buyer's partner, after a further 22.5 lakh shares bought on the market at ₹723.28 (₹162.74 Cr)
TOTAL COST₹1,750 Cr including ₹50 Cr of expenses (other reports: ₹1,360 Cr, ₹1,369.51 Cr at signing)
FUNDING₹300 Cr term loan plus about ₹1,450 Cr of non-voting instruments from investors led by Bain Capital, including Trust Group and Investec
OPEN OFFER26%, up to 2,77,26,848 shares at ₹299, up to ₹829.03 Cr
COMBINED GROUPPro forma revenue above ₹4,000 Cr and EBITDA about ₹834 Cr across Anupam, Tanfac, Jayhawk and Bliss GVS (company statement); Bliss GVS pro forma revenue ₹927 Cr
THE ACCESS POINT Both companies are listed. Anupam Rasayan and Bliss GVS Pharma shares trade on NSE and BSE and can be bought in the market.

Executive decision summary

THE BOTTOM LINEAnupam Rasayan, a custom-synthesis chemicals maker, took control of Bliss GVS Pharma, a formulations exporter, in a deal reported at about ₹1,750 crore. The agreement was signed on 23 May 2026 and the 47.95% promoter block was bought on 28 September 2026 at ₹299 a share. A further 22.5 lakh shares were bought on the market at ₹723.28, far above the ₹299 contract price, taking the combined holding to about 50.07%. The money came from a ₹300 crore term loan and about ₹1,450 crore of non-voting instruments from investors led by Bain Capital. Bliss GVS earned a reported ₹134.73 crore profit on about ₹1,000 crore of income in FY26 and has almost no debt. The record has conflicts: stake percentage, total cost and the buyer's FY26 and the target's revenue differ across outlets.
WHICH INVESTORThe deal fits a pharma and chemicals watcher IF you follow Indian companies using outside capital to buy control of listed pharma units. Wait IF you need a clean price, the legal form of the ₹1,450 crore instruments or Bliss GVS EBITDA: none was confirmed.
COMFORT FITCustom synthesis = making specialty chemicals to a customer's order, often for pharma or agriculture. Formulations = finished medicines such as tablets, as against the raw chemicals that go into them. Non-voting instruments = money put in for a return but with no vote, so the buyer keeps control. Person acting in concert = a related party counted together with the buyer for stake and open-offer purposes.
THE RUPEIA NUMBER₹299 against ₹723.28. The contract price per share for the promoter block, against the price paid for 22.5 lakh shares on the market, which was 2.4 times as high.

1 CLAIM REGISTER: EVIDENCE GRADING

ClaimSourceGradeRupeia assessment
SPA signed 23 May 2026; promoter block 47.95% completed 28 Sep at ₹299Medical Dialogues; Indian Pharma Post; WhalesbookCEstablished
Total cost ₹1,750 Cr including ₹50 Cr expensesMedical Dialogues; Indian Pharma PostCReported total
Combined stake 50.07% (48.2% in Indian Pharma Post and Medical Dialogues headlines; 43.3% or up to 74.2% at signing)VariousDConflict across outlets
Funding: ₹300 Cr loan plus about ₹1,450 Cr of non-voting instruments led by Bain CapitalIndian Pharma Post; Medical DialoguesCLegal form not published in sources read
Bliss GVS FY26 PAT ₹134.73 Cr; income ₹1,000.64 CrWhalesbookCSingle detailed source; revenue ranges ₹809–1,015 Cr elsewhere
Seller namesWhalesbook (aggregator)DNot checked against a filing

2 THE DEAL: STAKE, PRICE AND OPEN OFFER

ItemDetail
Promoter block5,09,84,595 shares, 47.95%, at ₹299 (another report prints 5,09,86,264)
On-market top-up22,50,000 shares at ₹723.28, ₹162.74 Cr
Open offer26%, up to 2,77,26,848 shares at ₹299, up to ₹829.03 Cr; call option on 51,81,571 shares (4.90%)
Figure at signing in May"Over ₹1,360 Cr" for up to 74.2% (Venture Intelligence); ₹1,369.51 Cr for 43.3% (Whalesbook)
Sellers (aggregator)Promoters Shruti Vishal Rao, Vibha Gagan Sharma and Narsimha Shibroor Kamath; non-promoters Gautam Rasiklal Ashra, Arjun Gautam Ashra and Gulbarga Trading and Investment; sellers' counsel Kanga & Co
Promoter holding beforeReported at 35.01% in June 2026 (Multibagg)
Calculation (Rupeia)Result
Cost of the promoter block5,09,84,595 × ₹299 ≈ ₹1,524 Cr
Top-up check22,50,000 × ₹723.28 = ₹162.7 Cr, matching ₹162.74 Cr
Sum with ₹50 Cr of expenses₹1,524 Cr + ₹163 Cr + ₹50 Cr ≈ ₹1,737 Cr, within 0.7% of the ₹1,750 Cr headline
Total shares in the company2,77,26,848 ÷ 26% ≈ 10.66 crore (the promoter block gives 10.63 crore)
Top-up share of the company22.5 lakh ÷ 10.65 crore ≈ 2.1%; 47.95% + 2.1% = 50.06%, matching 50.07%
Open offer maximum2,77,26,848 × ₹299 = ₹829.0 Cr
Top-up price against contract price₹723.28 ÷ ₹299 = 2.42x
RUPEIA READ The headline cost makes sense only if the on-market purchase is counted: the promoter block at ₹299 plus the top-up and expenses lands within a rounding gap of ₹1,750 crore. The price gap, ₹299 on the contract against ₹723.28 on the market, is large and the sources do not explain it. If the shares were trading near ₹723, the ₹299 open offer sits far below the market, as in the Novartis India deal (Report 56), and few public holders would tender.

3 FUNDING: WHO PAID FOR CONTROL

Source of moneyAmountDetail
Term loan₹300 CrLender not named in sources read
Non-voting instrumentsAbout ₹1,450 CrInvestors led by Bain Capital, with Trust Group and Investec; legal form and terms not published
TotalAbout ₹1,750 CrMatches the headline cost
Calculation (Rupeia)Result
Outside instruments as share of total₹1,450 Cr ÷ ₹1,750 Cr = 83%
Term loan as share of total₹300 Cr ÷ ₹1,750 Cr = 17%
Anupam FY26 profit against the instruments₹222 Cr ÷ ₹1,450 Cr = 15% a year, before any return owed on the instruments
RUPEIA READ More than four-fifths of the money came from outside investors in instruments that carry no vote. That keeps control with the Desai family but means the instruments will take a return from Anupam and Bliss GVS cash flows. Without the terms, the cost of that capital and any repayment schedule cannot be assessed. This is the largest disclosure gap in the deal.

4 THE TARGET: BLISS GVS PHARMA

Measure (FY26, to 31 Mar 2026)ValueSource quality
Total income₹1,000.64 Cr, up 18.25% from ₹846.22 CrWhalesbook
Revenue elsewhere₹927 Cr (pro forma), ₹809.73 Cr and ₹1,015.45 CrOther outlets
Profit after tax₹134.73 Cr against ₹96.87 Cr (reported as up 49%)Whalesbook
Net worth₹1,231.76 CrWhalesbook
Borrowings₹2.93 CrWhalesbook
EBITDANot confirmed; an aggregator lists ₹238 Cr; Q4 EBITDA ₹55.63 Cr (secondary)Aggregators
ExportsAbout 91% of sales, Sub-Saharan Africa about 80%Aggregator summary, not verified
Capacity useAbout 30%, target 70–80%, no timelineMedical Dialogues; Indian Pharma Post
Calculation (Rupeia)Result
Profit growth check₹134.73 Cr ÷ ₹96.87 Cr − 1 = 39.1%, not the 49% reported
Revenue growth check₹1,000.64 Cr ÷ ₹846.22 Cr − 1 = 18.25%, as reported
Profit margin on total income₹134.73 Cr ÷ ₹1,000.64 Cr = 13.5%
Equity value of 100% at ₹29910.66 crore × ₹299 ≈ ₹3,188 Cr
Price to earnings at ₹299₹3,188 Cr ÷ ₹134.73 Cr ≈ 23.7x
Price to book at ₹299₹3,188 Cr ÷ ₹1,231.76 Cr ≈ 2.6x
Equity value at ₹723.2810.66 crore × ₹723.28 ≈ ₹7,710 Cr, about 57x FY26 profit
RUPEIA READ The earlier research note estimated about 13 times earnings by dividing ₹1,750 crore by profit, but that mixes the cost of a half stake with the profit of the whole company. Valuing the whole company at the ₹299 contract price gives about 24 times earnings and 2.6 times book value, with almost no debt. At the ₹723 top-up price, the same arithmetic gives about 57 times earnings. The reported 49% profit growth does not match the two profit figures, which give 39%, so one of the numbers needs checking.

5 THE BUYER: ANUPAM RASAYAN

MeasureValueSource quality
FY26 revenue₹2,383.6 Cr, up about 65% (MarketsMojo shows ₹2,365.46 Cr)Whalesbook
FY26 EBITDA and PAT₹543 Cr (23%) and ₹222 CrSecondary sources
Q1 FY27 revenue₹654.98 Cr, up about 35%; EBITDA ₹162 Cr (24.8%) or ₹174.9 Cr (26.2%)Indian Pharma Post
FY27 growth guidanceOver 30%, raised from 20–25%Sahi
Pro forma combinedRevenue above ₹4,000 Cr: Anupam ₹1,676 Cr, Tanfac ₹711 Cr, Jayhawk ₹722 Cr, Bliss GVS ₹927 Cr; EBITDA about ₹834 CrCompany statement via Medical Dialogues
Earlier dealsTanfac Industries 24.96% (2022); Jayhawk Fine Chemicals (Kansas, US) 100%, enterprise value about US$134m, closed 27 Feb 2026Venture Intelligence; The Week
Calculation (Rupeia)Result
Components of the ₹4,000 Cr claim₹1,676 + ₹711 + ₹722 + ₹927 = ₹4,036 Cr
Pro forma EBITDA margin₹834 Cr ÷ ₹4,036 Cr = 20.7%, below Anupam's own 23%
Bliss GVS share of the pro forma revenue₹927 Cr ÷ ₹4,036 Cr = 23%
Anupam FY26 EBITDA margin₹543 Cr ÷ ₹2,383.6 Cr = 22.8%

Anand Desai is Managing Director of Anupam Rasayan and has been with the company since 1992. Mona Desai is Vice Chairman and Whole-Time Director. Ravi Desai became Chief Operating Officer on 14 August 2026. No chief executive is named in the sources read. A Tech Mahindra link suggested in the research brief was not found in any source.

RUPEIA READ Anupam has used outside capital three times in about three years: Tanfac, Jayhawk and now Bliss GVS. Its pro forma margin of 20.7% is below its standalone margin of 22.8%, which means the acquired businesses dilute margin until capacity use at Bliss GVS rises from about 30%. No timeline for that has been published.

6 SECTOR CONTEXT: PHARMA M&A IN 2026

DatapointDetailSource
September 2026 healthcare M&A₹19 bn from three main deals; pharma 88.8% of value; healthtech 10%Equirus via Indian Pharma Post, 6 Oct 2026
Year to datePharma 91.4% of healthcare M&A value; calendar 2025 share 71%Equirus
Other September dealRPG Active Pharma buys Raghava Life Sciences' API and intermediates business for ₹135 CrIndian Pharma Post
Q3 2026 deal volume87 deals, US$4.3bn, a record numberGrant Thornton
Largest 2026 deal mentionedSun Pharma and Organon, US$11.8bn, announced April 2026Grant Thornton
RUPEIA READ Pharma is taking an unusually large share of healthcare deal value in 2026, and buyers range from private equity (ChrysCapital, Creador) to chemical companies moving downstream into finished medicines. Anupam is an example of the second type: a supplier of ingredients buying a formulations company with its own markets.

7 RISKS, SCENARIOS AND CHECKLIST

RiskEvidenceSeverityKill condition
Disclosure on funding₹1,450 Cr of instruments, terms unpublishedHIGHReturn and repayment terms prove heavy
Price conflicts₹299 contract vs ₹723.28 top-up; stake 43–50%MEDIUMFiling shows higher effective cost
Margin dilutionPro forma 20.7% against 22.8%MEDIUMBliss GVS utilisation stays near 30%
ConcentrationExports about 91%, Sub-Saharan Africa about 80% (aggregator)MEDIUMAfrican demand or payment shocks
Leverage₹300 Cr term loan plus instrumentsMEDIUMCash flow below service needs
Evidence qualitySeller names and Bliss GVS EBITDA from aggregatorsMEDIUMFilings differ
ScenarioWhat happensOutcome
BullUtilisation rises to 70%; platform reaches ₹4,000 Cr revenueMargins recover
BaseSlow ramp-up; instruments serviced from cash flowModerate return
BearExport shock and heavy instrument costsProfit squeezed
Investor classFitWhy
Listed-market investor in AnupamPARTIALGrowth guidance over 30%, but funding terms unknown
Listed-market investor in Bliss GVSWAITOpen-offer outcome and price gap unclear
Short-term traderLOWEvents: open-offer completion and instrument terms

Rupeia does not recommend buying or selling any security and is not a SEBI-registered investment adviser or research analyst. Open items are the terms of the instruments, the open-offer result and Bliss GVS EBITDA.

8 KEY TERMS USED IN THIS REPORT

The terms below are used in this report. Each is explained in plain words.

TermMeaning
Person acting in concert (PAC)A related party counted with the buyer for stake and open-offer rules.
Non-voting instrumentAn investment that earns a return but carries no vote.
Custom synthesisMaking specialty chemicals to a customer's specification.
FormulationsFinished medicines such as tablets and syrups.
Open offerA required offer to buy 26% from public shareholders after control changes.
Pro formaResults shown as if the deal had been in place for the whole period.

Frequently asked questions

What did Anupam Rasayan buy?

Control of Bliss GVS Pharma, through a promoter block of 47.95% bought at ₹299 a share, completed on 28 September 2026, plus a market purchase that took its combined holding to about 50.07%.

How much did it cost?

About ₹1,750 crore including ₹50 crore of expenses, according to Medical Dialogues and Indian Pharma Post. Earlier reports in May gave about ₹1,360 crore.

How was it funded?

A ₹300 crore term loan and about ₹1,450 crore of non-voting instruments from investors led by Bain Capital, with Trust Group and Investec.

What is the open offer?

26% of Bliss GVS, up to 2,77,26,848 shares at ₹299, worth up to ₹829 crore if fully accepted.

What does Bliss GVS earn?

FY26 total income of about ₹1,000 crore and profit after tax of ₹134.73 crore, with borrowings of ₹2.93 crore, per Whalesbook. Other outlets give different revenue.

What is the combined group's size?

The company says pro forma revenue is above ₹4,000 crore and EBITDA about ₹834 crore, including Tanfac and Jayhawk.

Source log

Indian Pharma Post: Anupam Rasayan completes ₹1,750 Cr acquisition of Bliss GVS Pharma

Medical Dialogues: Anupam acquires 48.2% in Bliss GVS Pharma for ₹1,750 Cr

Bar & Bench: Anupam controlling stake; Kanga & Co advises sellers

Venture Intelligence: Anupam to acquire Bliss GVS Pharma (₹1,360 Cr)

Whalesbook: Bliss GVS FY26 results

Whalesbook: Anupam to acquire 26% via ₹299 open offer

Whalesbook: Anupam FY26 revenue up 65%

Indian Pharma Post: Pharma dominates Indian healthcare M&A

The Week: Anupam Rasayan completes US$150m Jayhawk acquisition

Grant Thornton: Pharma and Healthcare Dealtracker Q3 2026

DISCLAIMER This document is published strictly for informational, educational and academic record-keeping purposes. The publisher is not a SEBI Registered Investment Adviser (RIA) or Research Analyst (RA). It does not constitute personal investment advice, a financial recommendation, or an offer or solicitation to buy, sell or subscribe to any securities. Investments in the securities market are subject to market risks. Read all related documents carefully before investing.